Vigil Neuroscience, Inc., (VIGL) News

Vigil Neuroscience, Inc., (VIGL): $7.75

0.65 (+9.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VIGL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 397

in industry

Filter VIGL News Items

VIGL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest VIGL News From Around the Web

Below are the latest news stories about Vigil Neuroscience Inc that investors may wish to consider to help them evaluate VIGL as an investment opportunity.

Wall Street gyrations may thwart deal closings, IPO outlook

In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.

Yahoo | January 27, 2022

New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

Whether you're new to the stock market or have been investing for years, initial public offerings (IPOs) can be exciting. An IPO happens when a company begins offering shares of stock for the first time. Could any of these three IPOs be a good fit for your portfolio?

Yahoo | January 27, 2022

Newly listed Amylyx, Vigil Neurosciences and CinCor rebound after falling below IPO prices

Amylyx Pharmaceuticals, Vigil Neurosciences and CinCor Pharma all gained ground Tuesday after falling below their IPO prices on Monday.

Seeking Alpha | January 11, 2022

Vigil Neuroscience Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the closing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds of the offering were $98 million, before deducting underwriting discounts and commissions and other offering

Yahoo | January 11, 2022

Vigil Neuroscience Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Vigil Neuroscience. The gross proceeds of the offering, before deducting underwriting di

Yahoo | January 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.445 seconds.